- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Ind-Swift Laboratories Ltd. has announced a board meeting concerning a Nil Statement on the deviation in the utilization of funds raised through the preferential issue of convertible warrants. For the quarter ended 30 September 2024, the company confirmed that the funds amounting to ₹78.73 crore (from a total issue size of ₹314.60 crore) were fully utilized as per the stated objectives without any deviations.
This update reinforces the company's commitment to transparency and effective fund management, likely enhancing investor confidence. The confirmed use of proceeds as planned may be perceived positively by investors, reflecting operational stability and governance. Overall, this development suggests a consistent execution of their strategic initiatives.